In Reply Hugon-Rodin et al and Joffe and Hickey1 raise questions about the safety and advisability of hormone therapy (HT) in the treatment and/or prevention of depression in perimenopausal women, as HT (in the wake of the Women’s Health Initiative2) is recommended only for the management of acute perimenopausal symptoms. In response to their concerns, we would like to point out the following.